Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology

Akshanth R. Polepally, Rory P Remmel, Richard Brundage, Ilo E Leppik, John O. Rarick, R. Eugene Ramsay, Angela K Birnbaum

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A classic 2-period crossover bioavailability study was conducted to evaluate the relative and absolute bioavailability of immediate-release (IR) and extended-release (XR) lamotrigine formulations under steady-state conditions in elderly patients with epilepsy. On treatment days, each subject's morning dose (IR or XR lamotrigine) was replaced with an intravenous 50-mg dose of stable-labeled lamotrigine. Lamotrigine concentrations were measured at 13 points between 0 and 96 hours. XR and IR lamotrigine formulations were similar with respect to steady-state area under the concentration-time curve from 0 to 24 hours (AUC0-24h ss), average concentration (Cavg, ss), and trough concentration (Cτ, ss). A 33% lower fluctuation in concentrations with XR was observed relative to IR lamotrigine. The time to peak concentration (Tmax, ss) was delayed for XR lamotrigine (3.0 vs 1.3 hours) with lower peak concentration (15% lower). The absolute bioavailability for IR and XR formulations was 73% and 92%, respectively. The formulations were bioequivalent with respect to AUC0-24h ss, Cτ, ss, and Cavg, ss indicating that it may be possible to switch directly from IR to XR lamotrigine without changes in the total daily dose.

Original languageEnglish (US)
Pages (from-to)1101-1108
Number of pages8
JournalJournal of Clinical Pharmacology
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Isotopes
Biological Availability
Epilepsy
Pharmacokinetics
lamotrigine
Cross-Over Studies

Keywords

  • elderly
  • extended-release
  • immediate-release
  • lamotrigine
  • stable isotope

Cite this

@article{1120ae487882455d828423bc0c7f6834,
title = "Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology",
abstract = "A classic 2-period crossover bioavailability study was conducted to evaluate the relative and absolute bioavailability of immediate-release (IR) and extended-release (XR) lamotrigine formulations under steady-state conditions in elderly patients with epilepsy. On treatment days, each subject's morning dose (IR or XR lamotrigine) was replaced with an intravenous 50-mg dose of stable-labeled lamotrigine. Lamotrigine concentrations were measured at 13 points between 0 and 96 hours. XR and IR lamotrigine formulations were similar with respect to steady-state area under the concentration-time curve from 0 to 24 hours (AUC0-24h ss), average concentration (Cavg, ss), and trough concentration (Cτ, ss). A 33{\%} lower fluctuation in concentrations with XR was observed relative to IR lamotrigine. The time to peak concentration (Tmax, ss) was delayed for XR lamotrigine (3.0 vs 1.3 hours) with lower peak concentration (15{\%} lower). The absolute bioavailability for IR and XR formulations was 73{\%} and 92{\%}, respectively. The formulations were bioequivalent with respect to AUC0-24h ss, Cτ, ss, and Cavg, ss indicating that it may be possible to switch directly from IR to XR lamotrigine without changes in the total daily dose.",
keywords = "elderly, extended-release, immediate-release, lamotrigine, stable isotope",
author = "Polepally, {Akshanth R.} and Remmel, {Rory P} and Richard Brundage and Leppik, {Ilo E} and Rarick, {John O.} and Ramsay, {R. Eugene} and Birnbaum, {Angela K}",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/jcph.522",
language = "English (US)",
volume = "55",
pages = "1101--1108",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients

T2 - Use of stable isotope methodology

AU - Polepally, Akshanth R.

AU - Remmel, Rory P

AU - Brundage, Richard

AU - Leppik, Ilo E

AU - Rarick, John O.

AU - Ramsay, R. Eugene

AU - Birnbaum, Angela K

PY - 2015/10/1

Y1 - 2015/10/1

N2 - A classic 2-period crossover bioavailability study was conducted to evaluate the relative and absolute bioavailability of immediate-release (IR) and extended-release (XR) lamotrigine formulations under steady-state conditions in elderly patients with epilepsy. On treatment days, each subject's morning dose (IR or XR lamotrigine) was replaced with an intravenous 50-mg dose of stable-labeled lamotrigine. Lamotrigine concentrations were measured at 13 points between 0 and 96 hours. XR and IR lamotrigine formulations were similar with respect to steady-state area under the concentration-time curve from 0 to 24 hours (AUC0-24h ss), average concentration (Cavg, ss), and trough concentration (Cτ, ss). A 33% lower fluctuation in concentrations with XR was observed relative to IR lamotrigine. The time to peak concentration (Tmax, ss) was delayed for XR lamotrigine (3.0 vs 1.3 hours) with lower peak concentration (15% lower). The absolute bioavailability for IR and XR formulations was 73% and 92%, respectively. The formulations were bioequivalent with respect to AUC0-24h ss, Cτ, ss, and Cavg, ss indicating that it may be possible to switch directly from IR to XR lamotrigine without changes in the total daily dose.

AB - A classic 2-period crossover bioavailability study was conducted to evaluate the relative and absolute bioavailability of immediate-release (IR) and extended-release (XR) lamotrigine formulations under steady-state conditions in elderly patients with epilepsy. On treatment days, each subject's morning dose (IR or XR lamotrigine) was replaced with an intravenous 50-mg dose of stable-labeled lamotrigine. Lamotrigine concentrations were measured at 13 points between 0 and 96 hours. XR and IR lamotrigine formulations were similar with respect to steady-state area under the concentration-time curve from 0 to 24 hours (AUC0-24h ss), average concentration (Cavg, ss), and trough concentration (Cτ, ss). A 33% lower fluctuation in concentrations with XR was observed relative to IR lamotrigine. The time to peak concentration (Tmax, ss) was delayed for XR lamotrigine (3.0 vs 1.3 hours) with lower peak concentration (15% lower). The absolute bioavailability for IR and XR formulations was 73% and 92%, respectively. The formulations were bioequivalent with respect to AUC0-24h ss, Cτ, ss, and Cavg, ss indicating that it may be possible to switch directly from IR to XR lamotrigine without changes in the total daily dose.

KW - elderly

KW - extended-release

KW - immediate-release

KW - lamotrigine

KW - stable isotope

UR - http://www.scopus.com/inward/record.url?scp=84940892669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940892669&partnerID=8YFLogxK

U2 - 10.1002/jcph.522

DO - 10.1002/jcph.522

M3 - Article

C2 - 25903807

AN - SCOPUS:84940892669

VL - 55

SP - 1101

EP - 1108

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 10

ER -